Showing results (1631-1640 of 2,456) with videos related to

Sort By:
Pageof 246
International Journal of Cancer|March 20, 1998
Pre-clinical evaluation of the Gastrimmune immunogen alone and in combination with 5-fluorouracil/leucovorin in a rat colorectal cancer modelS A Watson, D Michael, T A Justin, et al.
Non-Coding RNA Research|August 31, 2018
Translational applications of microRNAs in cancer, and therapeutic implicationsGrace T Kwok, Jing Ting Zhao, Jocelyn Weiss, et al.
The Plant Cell|September 11, 2001
Secretory bulk flow of soluble proteins is efficient and COPII dependentB A Phillipson, P Pimpl, L L daSilva, et al.
Hypertension (Dallas, Tex. : 1979)|February 19, 1999
Myocardial osteopontin expression coincides with the development of heart failureK Singh, G Sirokman, C Communal, et al.
Clinical Endocrinology|February 1, 1994
Corticotrophin releasing hormone levels in human plasma and amniotic fluid during gestationR L Emanuel, B G Robinson, E W Seely, et al.
Endocrine-Related Cancer|February 17, 2009
Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomasP S H Soon, A J Gill, D E Benn, et al.
The Oncologist|July 12, 2008
Pheochromocytoma: current approaches and future directionsJoel T Adler, Goswin Y Meyer-Rochow, Herbert Chen, et al.
International Journal of Radiation Oncology, Biology, Physics|August 23, 2005
Long-term survival and functional status of patients with low-grade astrocytoma of spinal cordClifford G Robinson, Richard A Prayson, Joseph F Hahn, et al.
The Journal of Clinical Endocrinology and Metabolism|May 2, 2013
Familial SDHA mutation associated with pituitary adenoma and pheochromocytoma/paragangliomaTrisha Dwight, Kirsty Mann, Diana E Benn, et al.
BMC Cardiovascular Disorders|September 22, 2014
Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trialsHelen M Colhoun, Jennifer G Robinson, Michel Farnier, et al.
Pageof 246